Literature DB >> 33440673

LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis.

Aleksandra Gąsecka1, Sylwester Rogula1, Łukasz Szarpak2,3, Krzysztof J Filipiak1.   

Abstract

Atherosclerosis and its complications, including acute coronary syndromes, are the major cause of death worldwide. The two most important pathophysiological mechanisms underlying atherosclerosis include increased platelet activation and increased low-density lipoproteins (LDL) concentration. In contrast to LDL, oxidized (ox)-LDL have direct pro-thrombotic properties by functional interactions with platelets, leading to platelet activation and favoring thrombus formation. In this review, we summarize the currently available evidence on the interactions between LDL-cholesterol and platelets, which are based on (i) the presence of ox-LDL-binding sites on platelets, (ii) generation of ox-LDL by platelets and (iii) the role of activated platelets and ox-LDL in atherosclerosis. In addition, we elaborate on the clinical implications of these interactions, including development of the new therapeutic possibilities. The ability to understand and modulate mechanisms governing interactions between LDL-cholesterol and platelets may offer new treatment strategies for atherosclerosis prevention.

Entities:  

Keywords:  LDL-cholesterol; atherosclerosis; extracellular vesicles; platelets; treatment

Year:  2021        PMID: 33440673      PMCID: PMC7826814          DOI: 10.3390/life11010039

Source DB:  PubMed          Journal:  Life (Basel)        ISSN: 2075-1729


  83 in total

1.  Oxidized low-density lipoprotein-dependent platelet-derived microvesicles trigger procoagulant effects and amplify oxidative stress.

Authors:  Hua Wang; Zhi-Hao Wang; Jing Kong; Meng-Yun Yang; Gui-Hua Jiang; Xu-Ping Wang; Ming Zhong; Yun Zhang; Jing-Ti Deng; Wei Zhang
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

Review 2.  Low-density lipoprotein-lowering medication and platelet function.

Authors:  Patrizia Ferroni; Stefania Basili; Francesca Santilli; Giovanni Davì
Journal:  Pathophysiol Haemost Thromb       Date:  2006

Review 3.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

4.  Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms.

Authors:  Arunima Ghosh; Gurunathan Murugesan; Kan Chen; Li Zhang; Qing Wang; Maria Febbraio; Rita Marie Anselmo; Kandice Marchant; John Barnard; Roy L Silverstein
Journal:  Blood       Date:  2011-04-08       Impact factor: 22.113

5.  Human platelets exclusively bind oxidized low density lipoprotein showing no specificity for acetylated low density lipoprotein.

Authors:  I Volf; T Moeslinger; J Cooper; W Schmid; E Koller
Journal:  FEBS Lett       Date:  1999-04-23       Impact factor: 4.124

Review 6.  Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease.

Authors:  Simon Barquera; Andrea Pedroza-Tobías; Catalina Medina; Lucía Hernández-Barrera; Kirsten Bibbins-Domingo; Rafael Lozano; Andrew E Moran
Journal:  Arch Med Res       Date:  2015-06-29       Impact factor: 2.235

7.  Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapy.

Authors:  Bernhard Jäger; Editha Piackova; Paul Michael Haller; Tijana Andric; Beatrice Kahl; Günther Christ; Alexander Geppert; Johann Wojta; Kurt Huber
Journal:  Arch Med Sci       Date:  2018-12-30       Impact factor: 3.318

Review 8.  Platelets Extracellular Vesicles as Regulators of Cancer Progression-An Updated Perspective.

Authors:  Magdalena Żmigrodzka; Olga Witkowska-Piłaszewicz; Anna Winnicka
Journal:  Int J Mol Sci       Date:  2020-07-22       Impact factor: 5.923

Review 9.  LOX-1, OxLDL, and atherosclerosis.

Authors:  Angela Pirillo; Giuseppe Danilo Norata; Alberico Luigi Catapano
Journal:  Mediators Inflamm       Date:  2013-07-10       Impact factor: 4.711

Review 10.  Regulation of platelet activation and thrombus formation by reactive oxygen species.

Authors:  Jianlin Qiao; Jane F Arthur; Elizabeth E Gardiner; Robert K Andrews; Lingyu Zeng; Kailin Xu
Journal:  Redox Biol       Date:  2017-09-08       Impact factor: 11.799

View more
  5 in total

Review 1.  Lipid Droplets, the Central Hub Integrating Cell Metabolism and the Immune System.

Authors:  Wei Zhang; Linyong Xu; Ling Zhu; Yifan Liu; Siwei Yang; Mingyi Zhao
Journal:  Front Physiol       Date:  2021-12-03       Impact factor: 4.566

2.  CYP2C19 polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study.

Authors:  Mingming Zhang; Li Meng; Yeshi Chen; Xiaohui Li; Lin Shi
Journal:  Front Cardiovasc Med       Date:  2022-08-22

3.  Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction.

Authors:  Zahra Lotfollahi; Ana P Q Mello; Francisco A H Fonseca; Luciene O Machado; Andressa F Mathias; Maria C Izar; Nagila R T Damasceno; Cristiano L P Oliveira; Antônio M F Neto
Journal:  PLoS One       Date:  2022-08-30       Impact factor: 3.752

4.  TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.

Authors:  Krzysztof J Filipiak; Miguel Camafort Babkowski; Matteo Cameli; Stefano Carugo; Claudio Ferri; Djamshid B Irisov; Krzysztof Narkiewicz; Ulugbek Nizamov; Leopoldo Pérez de Isla; Anna Tomaszuk-Kazberuk; Andrea Ungar; Aleksandra Gąsecka
Journal:  Cardiol J       Date:  2022-09-19       Impact factor: 3.487

Review 5.  Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia.

Authors:  Piotr Pęczek; Mateusz Leśniewski; Tomasz Mazurek; Lukasz Szarpak; Krzysztof J Filipiak; Aleksandra Gąsecka
Journal:  Life (Basel)       Date:  2021-05-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.